I te 21 o Paenga-whāwhā, 2026, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration kua tohua te HS-20093 mō te werohanga (risvutatug rezetecan) hei rongoā hou mō te maimoatanga o ngā tūroro e pangia ana e te mate pukupuku repeure kua ātete ki te whakakāhoretia, kua whiwhi kē i te rongoā homoni hou me te chemotherapy taxane. He tumanako hou tēnei ki ngā tūroro mate pukupuku repeure puta noa i te ao.
Ko te HS-20093 (HS-20093 / GSK5764227) he hononga paturopi-rongoā B7-H3 (ADC) i whakawhanakehia motuhaketia e Hansoh. I te Huihuinga Mate Pukupuku Genitourinary Genitourinary o te American Society of Clinical Oncology i te tau 2026 (ASCO GU 2026), i whakaaturia mana ngā hua mai i tētahi whakamātautau Wāhanga II tuwhera, maha-pokapū, ko ARTEMIS-003 (NCT06001255) te ingoa. I arotakehia e te rangahau te whai huatanga me te haumaru o te HS-20093 i roto i ngā tūroro he mate pukupuku repeure ātete-whakarewa metastatic (mCRPC) kua whanake haere i muri i te iti rawa i te kotahi raina o te rongoā pūnaha.
He mea whakatenatena ngā hua:
- **Mō ngā tūroro i rongoatia i mua ki ngā taxanes:** ko te reiti urupare whāinga (cORR) kua whakaūtia he 38.9%, ā, ko te reiti urupare prostate-specific antigen (PSA) (he hekenga ≥50%) he 40.7%.
- **Mō ngā tūroro kāore anō kia rongoatia ki ngā taxanes i mua:** ko te reiti urupare whāinga kāore anō kia whakaūtia (uORR) he 41.7%, ā, ko te reiti urupare PSA50 he 23.8%.
E whakaatu ana ēnei raraunga he nui, he roa hoki te kaha ārai-puku o te HS-20093 ahakoa te whakamahinga o te rongoā chemotherapy taxane i mua. Mō ngā tūroro kua pāngia e te mate kua roa e ātete ana, kua hoki anō rānei ki te mate i muri i te paerewa tiaki o nāianei (te rongoā homoni hou + te rongoā chemotherapy), he kōwhiringa hou, he whai hua hoki tēnei ki te taha haumanu.
**Me pēhea te uru atu a ngā tūroro o tāwāhi ki tēnei rongoā hou?**
Mena kei te whawhai koe, kei te whawhai rānei tētahi mema o te whānau ki te mate pukupuku repeure ātete-whakaweto matatau, ā, kāore koe i te makona, i te kore rānei e manawanui ki ngā kōwhiringa maimoatanga o nāianei, ka taea e koe te kōrero ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing ki te aromatawai i te tika mō te rongoā HS-20093. Hei whare motuhake e kaha ana ki te whakarato ratonga hauora o te ao, e whakapau kaha ana te Tari Ao o te hōhipera ki te whakarato i te tiaki oncology whānui ki ngā tūroro o te ao, tae atu ki te urunga atu ki ngā whakamātautau haumanu auaha me ngā maimoatanga hou.
**Whakapā mai inaianei:**
- **Tau Waea:** 400-880-3716
- **Tautuhi WeChat:** 17801183037
- **Īmēra:**
① 100085_010@163.com
② myimmnet@163.com
**Ngā Tuhipoka Hira:**
- I mua i te haerenga mai, me whakarite e ngā tūroro o tāwāhi ngā whakamāoritanga reo Pākehā/Hainamana o ngā pūkete hauora o mua (tae atu ki ngā pūrongo pathology, ngā whakamātautau whakaahua, me ngā pūkete o te chemotherapy me te rongoā homoni o mua) hei whakahaere i te aromatawai tere a te tākuta.
- Ka taea e tā mātou Tari Ao te āwhina ki ngā reta pōwhiri mō ngā visa hauora, ngā whakaritenga, me ngā ratonga whakamāori. Mō ngā pātai motuhake, whakapā mai ki a mātou mā ngā hongere i runga ake nei.
Wā tuku: 28 Paenga-whāwhā 2026